US Market Focus Allergy Therapeutics is Europe-focused with an explicit focus on expanding into the US market, presenting a sales opportunity to establish partnerships, distribution channels, and regulatory pathways to enter or scale in the US.

Pipeline Opportunity Strong late-stage potential in grass, tree, and house dust mite vaccines, plus a peanut allergy vaccine in pre-clinical development, offering upside for co-development partnerships, regional licensing, or early-access deals in targeted markets.

Financing Momentum Recent financing rounds totaling tens of millions USD/GBP indicate access to growth-capital, suggesting readiness for expanded clinical programs, manufacturing scale, or strategic collaborations to accelerate commercialization.

Clinical Presence Active participation in major allergy conferences (AAAAI/WAO) signals a high-visibility R&D posture and opportunities to sponsor or co-host educational events, driving awareness and lead generation among clinicians.

Strategic Leadership Recent additions to the board and executive team (CSO and independent directors) suggest a shift toward stronger strategic execution and governance, creating openings for advisory partnerships, alignment on market-entry plans, and joint development discussions.